Recent Findings from Hackensack Meridian School of Medicine Advance Knowledge in Mental Health Diseases and Conditions (AMCP Market Insights: Optimizing managed care approaches to treatment-resistant depression): Mental Health Diseases and Conditions

2026 SEP 03 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Fresh data on Mental Health Diseases and Conditions are presented in a new report. According to news reporting out of Los Angeles, California, by NewsRx editors, research stated, “Treatment-resistant depression (TRD) is a subset of major depressive disorder (MDD) most commonly defined as failure to respond to 2 or more antidepressant regimens despite adequate dose, duration, and adherence to treatment. The burden of TRD impacts individuals, families, and society, with outcomes such as decreased health-related quality of life and increased health care utilization and costs.”

Our news journalists obtained a quote from the research from the Hackensack Meridian School of Medicine, “To address the unmet need in many mental health conditions, psychedelic-assisted treatment such as psilocybin for TRD is emerging as a potential option. To discuss optimizing managed care approaches to TRD including the use of psilocybin, AMCP Market Insights virtually convened an expert panel of managed care stakeholders in March 2026. This article provides a qualitative summary of the panel discussion along with key insights and suggested payer practices meant to support informed coverage decisions and guide future work such as collaboration, research, and advocacy. Key insights underscore that there is a high unmet need in TRD and that mitigating barriers to care is a priority for payers. Perspectives on the current evidence for psilocybin in TRD are mixed; payers want additional data to compare treatments, elucidate the appropriate treatment population, and assess cost-effectiveness. Additionally, a primary challenge with psilocybin treatment will be an adequate network of mental health professionals to oversee administration and observation and to provide post-treatment care.”

According to the news editors, the research concluded: “Examples of suggested payer practices include education, collaboration, prioritizing behavioral health network readiness and quality, and mitigating barriers to care.”

This research has been peer-reviewed.

For more information on this research see: AMCP Market Insights: Optimizing managed care approaches to treatment-resistant depression. Journal of Managed Care & Specialty Pharmacy, 2026;32. Journal of Managed Care & Specialty Pharmacy can be contacted at: Acad Managed Care Pharmacy, 100 N Pitt St, 400, Alexandria, VA 22314-3134, USA.

Our news journalists report that additional information may be obtained by contacting Gary Small, Hackensack Meridian Health, Hackensack Meridian School of Medicine, Los Angeles, CA. Additional authors for this research include Bridget Flavin, Charles Dragovich, Charles Dragovich, Ryan Haumschild, Terry Richardson and Michael H. Shannon.

Publisher contact information for the Journal of Managed Care & Specialty Pharmacy is: Acad Managed Care Pharmacy, 100 N Pitt St, 400, Alexandria, VA 22314-3134, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)